TY - CHAP M1 - Book, Section TI - Chapter 91. Breast Cancer Vaccines A1 - Mittendorf, Elizabeth A. A1 - Czerniecki, Brian J. A1 - Peoples, George E. A2 - Kuerer, Henry M. PY - 2010 T2 - Kuerer's Breast Surgical Oncology AB - Advances in the molecular characterization of human tumors have led to increased interest in the development of targeted therapeutics to include monoclonal antibodies and cancer vaccines. Interest in the development of cancer vaccines has increased since these advances led to the identification of tumor-associated antigens (TAAs).1-3 TAAs expressed by tumors are able to elicit a specific immune response. In addition to having an antigen that serves as a target for the immune response, a successful tumor vaccine requires a platform to present the antigen to the immune system and an environment that is conducive to immune stimulation. The goal of researchers, therefore, has been to identify TAAs and deliver them to the immune system in the context of a vaccine with the appropriate secondary signals required to prompt a robust, protective immune response. SN - PB - The McGraw-Hill Companies CY - New York, NY Y2 - 2024/10/04 UR - accesssurgery.mhmedical.com/content.aspx?aid=6417577 ER -